PURCHASE ORDER
Active75N98026P01298
Department of Health and Human Services › National Institutes of Health › NATIONAL INSTITUTES OF HEALTH OLAO
$251.8K
obligated · signed 2 months ago
ROLE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS VERSUS DPP-4 INHIBITORS FOR ALCOHOL AND SUBSTANCE USE DISORDERS IN IMPROVING HIV-RELATED OUTCOMES AND PROVIDING HEALTH BENEFITS IN PEOPLE LIVING WITH HIV
Performance timeline
Start
Aug 24, 2026
Current end
Aug 23, 2027
Potential end
Aug 23, 2030
with all options
Loading status
Estimated start: Aug 23, 2029
YALE UNIV
Contract 75N98026P01298
UEI
FL6GV84CKN57
Parent Company
YALE UNIV
Capabilities & Certifications
Headquarters Location
Congressional District: 03
Current Obligation
$251,752
Base + Exercised Options
$251,752
Total Ceiling Value
$1,007,008
Contract Type
FIRM FIXED PRICE
NAICS
OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES
PSC
SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA
Place of Performance
Congressional District: 03
Awarding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH OLAO
Office
Funding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH NIDA
Office
Solicitation procedures, competition exceptions, labor standards and account totals.